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initial diagnostic test were identiﬁed from a multicenter database
using complete facility, physician and pharmacy data from two
large health care plans from 2003–05. 1-year downstream CAD-
related episodes of care were examined for patients after initial
MDCT or MPI. Costs were further sub-classiﬁed by utilization of
high-cost resources, including cardiac catheterization, percutane-
ous transluminal coronary angioplasty (PTCA), and coronary
artery bypass surgery (CABG). RESULTS: A total of 18,489
patients underwent either MDCT (n = 638) or MPS (n = 17,851)
testing during the study period. While costs per CAD-related
episodes were similar between MDCT and MPS groups ($5,878
vs. $6,079, p = 0.20), patients undergoing MDCT had fewer
total numbers of CAD-related episodes of care (4.246 vs. 5.065,
p < .0001). High-cost CAD test utilization was also lower for
MDCT patients compared to MPI patients for cardiac catheter-
ization (15.673 vs. 29.132, p < 0.0001), PTCA (0.940 vs. 2.341,
p = 0.020), and CABG (2.351 vs. 5.274, p = 0.001). After adjust-
ment for age, gender, baseline cardiovascular risk, and baseline
health status, one-year total CAD-related episodes of care costs
for MDCT were 16.4% lower than MPS, by an average of $800
(95% CI, $39-$1394) per patient. CONCLUSION: Patients
without known CAD who undergo MDCT as an initial diagnos-
tic test, compared to MPI, incurred fewer CAD-related episodes
of care and underwent fewer incident high-cost tests. These data
suggest that MDCT may be a potential cost-saving alternative to
MPS for initial evaluation of patients with suspected CAD.
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OBJECTIVES: The general objective of this study was to develop
an explicit pharmacoeconomic threshold for purposes of phar-
maceutical decision making in South Africa (SA). METHODS:
For the determination of a pharmacoeconomic threshold for
pharmaceutical decision-making in SA, the method of the WHO,
namely the “three-times-GDP per capita” approach, was used.
To determine the GDP per capita for each health care sector, i.e.
private and public, in SA it was needed to determine the income
and number of people in each sector. The GDP for the public
sector was calculated by dividing the income generated in
the public sector by the total income generated in SA and
then multiplying it by the total GDP (Total GDP according to
Statistics South Africa in 2006 = R1,726,688,000,000 (US$
246,700,000,000)). The same formula will be used to determine
the GDP for the private sector. To determine the total income in
each sector, data from the All Media Products Survey (AMPS)
was used. The average income was calculated in 2006 prices.
The number of people in the public sector is determined by using
the 2003 ASSA (Actuarial Society of South Africa) model, and
subtracting the number of medical scheme beneﬁciaries accord-
ing to the 2005–06 Council for Medical Schemes report.
RESULTS: The GDP for the public sector was estimated at
R990,831,925,794 and the GDP for the private sector at
R735,856,074,206. The total SA population was estimated
at 47,866,985, with the number of people in the private sector at
6,835,621 and 41,031,364 people utilising the public health care
sector. The GDP/capita in the private and public sector was
estimated as R107,650 and R24,148 respectively. CONCLU-
SION: The threshold for the private health care sector is
R322,950, for the public sector it is R72,444 and for SA the
threshold for pharmaceutical decision making is R108,218.
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OBJECTIVES: We aimed to evaluate the clinical outcome of
BMS and DES placement in coronary artery disease patients and
estimate the cost of BMS and DES placement in a Chinese popu-
lation. METHODS: It was a retrospective cross-sectional study.
We included all patients who underwent PCI with stent place-
ment of either DES or BMS in a tertiary public hospital in Hong
Kong over 4-month period. Patients were followed up for the
occurrence of MACE within 12 months of the index stent place-
ment. MACE was deﬁned as cardiac death, non-fatal myocardial
infarction and target lesion revascularization. Direct medical
costs were estimated based on the procedural cost, hospitaliza-
tion, medications, cardiac follow-up and repeated interventions
taken. RESULTS: This interim analysis included 184 patients.
Twelve-month MACE rate was 12.2% in BMS versus 3.4% in
DES (p = 0.042). Rate of cardiac death was 3.7% in BMS versus
0% in DES group (p = 0.110). The mean 12-month cost
per patient after index PCI was USD 8827.6  5634.0
(median = 7268.2) in DES and USD 7222.4  4538.1 (median =
6170.5) in BMS. On average, DES costs USD 1605.1 more than
BMS per patient. CONCLUSION: Routine usage of DES is more
costly than BMS that may discourage the use of DES in our
public hospital setting. This may be explained by the less than
expected difference in 12-month MACE between DES and BMS
in our population and the lower hospitalization costs in Hong
Kong. Further cost-effectiveness analysis will be conducted to
evaluate the differences between DES and BMS.
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OBJECTIVES: Dyslipidemia is a risk factor for coronary heart
disease (CHD), which remains a leading cause of U.S. mortality,
irrespective of sex, race/ethnicity, or age. Because the beneﬁts of
antilipidemics extend across patient characteristics, antilipidemic
initiation rates should not widely vary by patient demographics.
We conducted a large-scale retrospective claims analysis to
conﬁrm this assumption among newly-diagnosed adult dyslipi-
demic patients. METHODS: Nine-year (1997–2006) retrospec-
tive claims analysis of Florida Medicaid adults (18 years) who
had 1 year of data before and 3 years of data following their
ﬁrst dyslipidemia (ICD-9 272.X) diagnosis. Charlson Index
classiﬁed disease burden. Logistic regression examined odds
ratios. RESULTS: Among 231,110 dyslipidemic patients, 19,128
meeting eligibility criteria received antilipidemics during the
index period; 18,346 did not. Women were 8% less likely to
receive antilipidemics (OR 0.92, 95% CI 0.88–0.96, p = 0.0005)
than men. Treatment initiation rates among Hispanics did not
signiﬁcantly differ from Whites. Blacks were 23% less likely (OR
0.77, 95% CI 0.73–0.81, p < 0.0001), and Other Ethnicities/
Races 17% more likely (OR 1.17, 95% CI 1.11–1.24,
p < 0.0001) to receive antilipidemics during the follow-up period
than Whites. Patients aged 50–64 years were 17% more likely
(OR 1.17, 95% CI 1.10–1.25, p < 0.0001), and those aged
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18–49 years were 57% less likely (OR 0.43 95% CI 0.41–0.46,
p < 0.0001), to receive antilipidemics than patients 65 years
old. Patients with substantial disease burden (Charlson Index >1)
were 9% more likely to receive antilipidemics (OR 1.09, 95% CI
1.01–1.18, p = 0.024) than those with no or moderate disease
burden (Charlson1). CONCLUSION: Although CHD remains
a leading cause of U.S.mortality irrespective of sex, race/ethnicity,
or age, and antilipidemics beneﬁt patients across these demo-
graphic characteristics, we found that females, Blacks, and
younger (aged 18–50 years) Medicaid patients with dyslipidemia
were signiﬁcantly less likely to receive antilipidemics than their
male, White or older counterparts.
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OBJECTIVES: The purpose of this study was to compare the
survival of patients admitted to different types of hospitals for
their ﬁrst acute myocardial infarction (AMI), and to assess how
the deﬁnition of failure and different variables affect the results.
METHODS: The analysis utilized the Victorian Admitted Epi-
sodes Data Set from 1996–2005, which contains data on all
patients admitted to acute private and public hospitals in the
state of Victoria, Australia. A hazard model was used to model
time to failure, which was deﬁned either as 30-day mortality, or
readmission for subsequent AMI. Hospitals were grouped into
one of ﬁve types and these were included as explanatory
variables. Other control variables, including AMI location,
co-morbidities, treatments, and demographics, were added to the
model one by one in order to determine their effect on survival,
and on the effect of hospital type on survival. RESULTS: The
impact and signiﬁcance of hospital type on survival depended
strongly on the deﬁnition of failure. Large teaching hospitals had
signiﬁcantly higher failure rates than all other hospital types
when failure was deﬁned as readmissions, while this ordering
was almost reversed when failure was deﬁned as 30-day mortal-
ity. Controlling for planned and unplanned treatments did not
signiﬁcantly affect these results. Including indices of socio-
economic status ampliﬁed the effects when failure was deﬁned as
readmissions, but had no signiﬁcant effect otherwise. Location of
AMI was signiﬁcant only when failure was deﬁned as 30-day
mortality, and improved the relative performance of large
regional base and suburban hospitals. All other variables were
generally similar in both models. CONCLUSION: The effect of
hospital type on survival depended strongly on the deﬁnition of
failure and somewhat on the inclusion of certain control vari-
ables. The results suggest that comparing the effects of hospital
type using patient outcomes requires careful consideration.
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OBJECTIVES: To evaluate degree of implementation of the
American and European guidelines related to the treatment as
secondary prevention, in the management of patients with acute
myocardial infarction with ST segment elevation (STEMI).
METHODS: Cross-sectional and multicentric study realized in
cardiology outpatient clinics in Spain. Physicians included con-
secutively outpatients over 18 years with STEMI happened
within 2 previous years. The guidelines of reference were the
American College of Cardiology/American Heart Association
(ACC/AHA 2004) and European Society of Cardiology (ESC
2003). Descriptive statistics and comparison of averages (“t” of
Student and Or of Mann-Whitney) and proportions (Chi-
squared) were realized with SAS package. RESULTS: A total
of 1439 out of 1588 patients were valid for analysis (90.6%).
A total of 80.3% were males, middle age were 62.4 years-
old (STD = 11.8) and the average BMI was of 27.8 Kg/m2
(STD = 3.7). The most frequent concomitant diseases were
hypertension (53.6%) and diabetes mellitus type II (28.5%). The
average of time after STEMI was 9.6 months (STD = 7.2). The
treatments more frequently used were statins (93.6%), aspirin
(93.2%) and beta-blockers (83.5%). The treatments used in
accordance with guidelines were antiaggregants/anticoagulants
(99.7% in both guidelines), statins (94.4% in ACC/AHA and
93.5% in ESC) and beta-blockers (83.5% in both guidelines),
staying in the second term ACE inhibitors/ARBs (78.2% ACC/
AHA and 59.7% ESC) and aldosterone antagonists (19.3%), this
one only recommended by the ACC/AHA. To summarize, 65.3%
(ACC/AHA) and 52.4% (ESC) of the patients were being treated
according guidelines. Regarding lifestyle factors, only 9.2%
(ACC/AHA) and 6.4% of patients followed the overall guide-
lines’ recommendations. CONCLUSION: This study shows a
low implementation of guidelines by Spanish physicians in man-
aging patients with STEMI, with more adherences to ACC/AHA
2004 than ESC 2003 guidelines. Treatment recommendations are
more followed than life-style recommendations. Based on this
study, actions are needed to increase adherence of Guidelines in
Spain.
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OBJECTIVES: Surveys evaluating plasma lipid goal attainment
in CHD patients prior to the updated European guidelines on
CVD prevention (Third Joint Task Force [TJTF]) showed that
hypercholesterolemia is inadequately treated. Limited data
accounts for the reasons behind this. The aim of this survey was
to evaluate the current use and efﬁcacy of lipid lowering drugs
(LLD), and to identify possible patient/physician characteristics
associated with failure to be at the TJTF guideline LDL-C target.
METHODS: An European multi-centre, cross sectional survey in
8 countries including patients on LLD for >3 months (stable
medication >6 weeks). One visit was scheduled for data collec-
tion including fasting lipids analysed by a central laboratory. In
all but 1 country physicians and patients ﬁlled in a questionnaire
about aspects of hypercholesterolemia and treatment. Data was
analysed centrally. Determination of individual LDL-C targets
followed 2003 TJTF guidelines including SCORE tables.
RESULTS: A total of 15,199 patients were recruited (14478
included in the ﬁnal analyses) with the following characteristics:
mean (SD) age 63.2 (11.3) yrs (45% females), waist circumfer-
ence 97.0 (13.3) cm. 62% had a history of hypertension, 18%
were smokers, 32% of the subjects had metabolic syndrome
(MS) according to the NCEPATP III criteria. Reason to prescribe
LLD: 67% primary prevention (PP), 33% secondary prevention
(SP) or familial hypercholesterolemia. 93% of the patients used
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